4//SEC Filing
Forbion Capital Fund IV Cooperatief U.A. 4
Accession 0000950170-24-140408
CIK 0001936258other
Filed
Dec 25, 7:00 PM ET
Accepted
Dec 26, 4:15 PM ET
Size
22.2 KB
Accession
0000950170-24-140408
Insider Transaction Report
Form 4
ForGrowth NAP B.V.
10% Owner
Transactions
- Sale
Ordinary Shares
2024-12-20$25.53/sh−44,143$1,126,993→ 10,807,853 total(indirect: See footnote) - Sale
Ordinary Shares
2024-12-20$26.13/sh−5,629$147,071→ 10,802,224 total(indirect: See footnote) - Sale
Ordinary Shares
2024-12-23$25.49/sh−25,132$640,625→ 10,777,092 total(indirect: See footnote) - Sale
Ordinary Shares
2024-12-24$25.66/sh−16,164$414,831→ 10,760,928 total(indirect: See footnote)
Footnotes (7)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024.
- [F2]Represents 19,388 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 24,755 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,807,853 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,155,680 are held by PoolCo and are allocated to ForGrowth,
- [F3](Continued from footnote 2) of which 4,094,330 shares are beneficially owned by Forbion Growth I and 6,061,350 shares are beneficially owned by Forbion IV.
- [F4]ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- [F5]Represents 2,472 shares sold on behalf of Forbion Growth I and 3,157 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.02 to $26.205. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,802,224 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,150,051 are held by PoolCo and are allocated to ForGrowth, of which 4,091,858 shares are beneficially owned by Forbion Growth I and 6,058,193 shares are beneficially owned by Forbion IV.
- [F6]Represents 11,038 shares sold on behalf of Forbion Growth I and 14,094 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.835. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,777,092 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,124,919 are held by PoolCo and are allocated to ForGrowth, of which 4,080,820 shares are beneficially owned by Forbion Growth I and 6,044,099 shares are beneficially owned by Forbion IV.
- [F7]Represents 7,099 shares sold on behalf of Forbion Growth I and 9,065 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.23 to $26.00. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,760,928 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,108,755 are held by PoolCo and are allocated to ForGrowth, of which 4,073,721 shares are beneficially owned by Forbion Growth I and 6,035,034 shares are beneficially owned by Forbion IV.
Documents
Issuer
NewAmsterdam Pharma Co N.V.
CIK 0001936258
Entity typeother
IncorporatedNetherlands
Related Parties
1- filerCIK 0001823747
Filing Metadata
- Form type
- 4
- Filed
- Dec 25, 7:00 PM ET
- Accepted
- Dec 26, 4:15 PM ET
- Size
- 22.2 KB